Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website. A replay will be available for at least 30 days following the presentation.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005829/en/
Xencor Inc. Aktie
Positive Stimmung für Xencor Inc. mit mehreren Buy- gegenüber Sell-Einschätzungen.
Das Kursziel von 31 € für Xencor Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 16.9 €.
